share_log

Goldman Sachs Maintains Neutral on Autolus Therapeutics, Raises Price Target to $4.8

Benzinga ·  Dec 13, 2023 09:32

Goldman Sachs maintains Autolus Therapeutics (NASDAQ:AUTL) with a Neutral and raises the price target from $3.2 to $4.8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment